Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Rating of “Buy” from Analysts

Scholar Rock Holding Corporation (NASDAQ:SRRK) has been assigned a consensus rating of “Buy” from the seventeen ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, twelve have given a buy recommendation and four have given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $54.3571.

Several brokerages recently weighed in on SRRK. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a research report on Thursday, January 22nd. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research report on Thursday, December 11th. HC Wainwright reaffirmed a “buy” rating and set a $58.00 target price on shares of Scholar Rock in a report on Tuesday, March 3rd. JPMorgan Chase & Co. boosted their target price on shares of Scholar Rock from $47.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, March 16th. Finally, Barclays increased their price target on shares of Scholar Rock from $52.00 to $53.00 and gave the stock an “overweight” rating in a report on Tuesday, March 3rd.

Insiders Place Their Bets

In other news, CFO Vikas Sinha sold 16,755 shares of the stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total transaction of $715,438.50. Following the sale, the chief financial officer directly owned 583,245 shares of the company’s stock, valued at $24,904,561.50. This represents a 2.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mo Qatanani sold 14,898 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $46.71, for a total value of $695,885.58. Following the completion of the transaction, the insider directly owned 85,660 shares of the company’s stock, valued at $4,001,178.60. The trade was a 14.82% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 207,464 shares of company stock valued at $9,157,423. Insiders own 13.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in SRRK. IFP Advisors Inc grew its stake in Scholar Rock by 294.1% in the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after acquiring an additional 450 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Scholar Rock during the fourth quarter worth $30,000. Summit Securities Group LLC purchased a new position in Scholar Rock during the fourth quarter valued at $31,000. Ramirez Asset Management Inc. acquired a new stake in shares of Scholar Rock in the third quarter valued at about $37,000. Finally, EverSource Wealth Advisors LLC grew its position in shares of Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after purchasing an additional 525 shares during the period. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Price Performance

NASDAQ:SRRK opened at $44.64 on Monday. The firm’s fifty day moving average is $45.18 and its two-hundred day moving average is $40.00. The firm has a market cap of $5.13 billion, a price-to-earnings ratio of -13.01 and a beta of 0.70. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.95 and a current ratio of 6.95. Scholar Rock has a one year low of $22.71 and a one year high of $49.82.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.10. During the same period in the previous year, the business posted ($0.64) EPS. Research analysts expect that Scholar Rock will post -2.42 EPS for the current year.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).